JP2012191939A5 - - Google Patents

Download PDF

Info

Publication number
JP2012191939A5
JP2012191939A5 JP2012129374A JP2012129374A JP2012191939A5 JP 2012191939 A5 JP2012191939 A5 JP 2012191939A5 JP 2012129374 A JP2012129374 A JP 2012129374A JP 2012129374 A JP2012129374 A JP 2012129374A JP 2012191939 A5 JP2012191939 A5 JP 2012191939A5
Authority
JP
Japan
Prior art keywords
seq
oligonucleotide
heg
immune response
ggttgt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012129374A
Other languages
English (en)
Japanese (ja)
Other versions
JP5775024B2 (ja
JP2012191939A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2012191939A publication Critical patent/JP2012191939A/ja
Publication of JP2012191939A5 publication Critical patent/JP2012191939A5/ja
Application granted granted Critical
Publication of JP5775024B2 publication Critical patent/JP5775024B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2012129374A 2004-09-01 2012-06-06 先天性免疫応答及び自己免疫疾患の阻害法及び阻害用組成物 Expired - Fee Related JP5775024B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60683304P 2004-09-01 2004-09-01
US60/606,833 2004-09-01

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2007530180A Division JP2008514187A (ja) 2004-09-01 2005-08-24 先天性免疫応答及び自己免疫疾患の阻害法及び阻害用組成物

Publications (3)

Publication Number Publication Date
JP2012191939A JP2012191939A (ja) 2012-10-11
JP2012191939A5 true JP2012191939A5 (cg-RX-API-DMAC7.html) 2013-01-24
JP5775024B2 JP5775024B2 (ja) 2015-09-09

Family

ID=36036819

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007530180A Pending JP2008514187A (ja) 2004-09-01 2005-08-24 先天性免疫応答及び自己免疫疾患の阻害法及び阻害用組成物
JP2012129374A Expired - Fee Related JP5775024B2 (ja) 2004-09-01 2012-06-06 先天性免疫応答及び自己免疫疾患の阻害法及び阻害用組成物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2007530180A Pending JP2008514187A (ja) 2004-09-01 2005-08-24 先天性免疫応答及び自己免疫疾患の阻害法及び阻害用組成物

Country Status (14)

Country Link
US (2) US8759305B2 (cg-RX-API-DMAC7.html)
EP (2) EP2305693B1 (cg-RX-API-DMAC7.html)
JP (2) JP2008514187A (cg-RX-API-DMAC7.html)
KR (1) KR101268877B1 (cg-RX-API-DMAC7.html)
CN (1) CN101052643B (cg-RX-API-DMAC7.html)
AU (2) AU2005282889B2 (cg-RX-API-DMAC7.html)
CA (1) CA2578775C (cg-RX-API-DMAC7.html)
DK (1) DK1794174T3 (cg-RX-API-DMAC7.html)
ES (2) ES2385657T3 (cg-RX-API-DMAC7.html)
NZ (1) NZ553581A (cg-RX-API-DMAC7.html)
PL (1) PL1794174T3 (cg-RX-API-DMAC7.html)
PT (1) PT1794174E (cg-RX-API-DMAC7.html)
SI (1) SI1794174T1 (cg-RX-API-DMAC7.html)
WO (1) WO2006028742A2 (cg-RX-API-DMAC7.html)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005282889B2 (en) 2004-09-01 2012-03-15 Dynavax Technologies Corporation Methods and conpositions for inhibition of innate immune responses and autoimmunity
CA2591582A1 (en) * 2004-12-17 2006-06-22 Dynavax Technologies Corporation Methods and compositions for induction or promotion of immune tolerance
DE102005005642A1 (de) * 2005-02-06 2006-08-10 Phenion Gmbh & Co. Kg Kosmetische oder pharmazeutische Zubereitungen enthaltend Nukleinsäuren, die zur Ausbildung von stem-loop-Sekundärstrukturen geeignete Sequenzen umfassen
SG160336A1 (en) 2005-03-04 2010-04-29 Dynavax Tech Corp Vaccines comprising oligonucleotides having immunostimulatory sequences (iss) wherein the iss are conjugated to antigens and stabilized by buffer conditions and further excipients
PL2179737T3 (pl) 2005-07-01 2014-01-31 Index Pharmaceuticals Ab Sposób do modulowania wrażliwości na steroidy
ES2450593T3 (es) 2005-07-01 2014-03-25 Index Pharmaceuticals Ab Método inmunoestimulante
WO2007047396A2 (en) 2005-10-12 2007-04-26 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response
US8895522B2 (en) 2005-10-28 2014-11-25 Index Pharmaceuticals Ab Composition and method for the prevention, treatment and/or alleviation of an inflammatory disease
JP2010536787A (ja) * 2007-08-15 2010-12-02 イデラ ファーマシューティカルズ インコーポレイテッド Toll様受容体モジュレータ
JP5749492B2 (ja) * 2007-10-26 2015-07-15 ダイナバックス テクノロジーズ コーポレイション 免疫応答と自己免疫を阻害する方法及び組成物
US8030289B2 (en) * 2008-08-06 2011-10-04 Changchun Huapu Biotechnology Co., Ltd. Oligonucleotide and use thereof
PT2154144E (pt) * 2008-08-06 2014-07-18 Changchun Huapu Biotechnology Co Ltd Oligonucleotídeos e utilização dos mesmos
CN102281880A (zh) * 2008-10-06 2011-12-14 艾德拉药物股份有限公司 类Toll受体抑制剂在高胆固醇血症和高脂血症及相关疾病的预防和治疗中的用途
EP2451974A2 (en) * 2009-07-08 2012-05-16 Idera Pharmaceuticals, Inc. Oligonucleotide-based compounds as inhibitors of toll-like receptors
WO2011159328A1 (en) * 2010-06-16 2011-12-22 Dynavax Technologies Corporation Methods of treatment using tlr7 and/or tlr9 inhibitors
BR112012032240A2 (pt) * 2010-06-16 2019-09-24 Dynavax Technologies Corporation método de tratamento utilizando inibidores tlr7 e/ou tlr9
WO2012040127A1 (en) 2010-09-22 2012-03-29 Alios Biopharma, Inc. Substituted nucleotide analogs
KR102100110B1 (ko) 2010-11-19 2020-04-14 이데라 파마슈티칼즈, 인코포레이티드 톨-유사 수용체 기반 면역 반응을 조절하기 위한 면역 조절 올리고뉴클레오타이드(iro) 화합물
CA2860234A1 (en) 2011-12-22 2013-06-27 Alios Biopharma, Inc. Substituted phosphorothioate nucleotide analogs
HK1206362A1 (zh) 2012-03-21 2016-01-08 Alios Biopharma, Inc. 硫代氨基磷酸酯核苷酸前藥的固體形式
NZ630805A (en) 2012-03-22 2016-01-29 Alios Biopharma Inc Pharmaceutical combinations comprising a thionucleotide analog
US9868955B2 (en) 2012-09-29 2018-01-16 Dynavax Technologies Corporation Human toll-like receptor inhibitors and methods of use thereof
US9228184B2 (en) 2012-09-29 2016-01-05 Dynavax Technologies Corporation Human toll-like receptor inhibitors and methods of use thereof
EP2754714A1 (en) * 2013-01-14 2014-07-16 Sarepta Therapeutics, Inc. Inhibitory oligonucleotides and their use in therapy
JP6873052B2 (ja) 2015-06-01 2021-05-19 サレプタ セラピューティクス,インコーポレイテッド Vii型コラーゲンにおけるアンチセンス誘導エクソン排除
WO2017173334A1 (en) 2016-04-01 2017-10-05 Checkmate Pharmaceuticals, Inc. Fc receptor-mediated drug delivery
WO2017214378A1 (en) 2016-06-08 2017-12-14 President And Fellows Of Harvard College Engineered viral vector reduces induction of inflammatory and immune responses
WO2018089695A1 (en) 2016-11-11 2018-05-17 Dynavax Technologies Corporation Toll-like receptor antagonist compounds and methods of use
JP6886854B2 (ja) * 2017-04-13 2021-06-16 シスメックス株式会社 被検物質の情報取得方法
WO2019094548A1 (en) 2017-11-08 2019-05-16 President And Fellows Of Harvard College Compositions and methods for inhibiting viral vector-induced inflammatory responses
EP3752194A4 (en) 2018-02-13 2022-03-16 Checkmate Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR TUMOR IMMUNOTHERAPY
AU2019251421B2 (en) 2018-04-09 2025-05-01 Checkmate Pharmaceuticals Packaging oligonucleotides into virus-like particles
US11863189B2 (en) * 2021-03-05 2024-01-02 Taiwan Semiconductor Manufacturing Company, Ltd. Input buffer circuit
US12110324B2 (en) 2022-07-22 2024-10-08 Flagship Pioneering Innovations Vi, Llc Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP)

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) * 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4948882A (en) 1983-02-22 1990-08-14 Syngene, Inc. Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis
US4650675A (en) 1983-08-18 1987-03-17 The Children's Medical Center Corporation Oligonucleotide conjugates
US5015733A (en) 1983-12-20 1991-05-14 California Institute Of Technology Nucleosides possessing blocked aliphatic amino groups
US5118802A (en) 1983-12-20 1992-06-02 California Institute Of Technology DNA-reporter conjugates linked via the 2' or 5'-primary amino group of the 5'-terminal nucleoside
US5118800A (en) 1983-12-20 1992-06-02 California Institute Of Technology Oligonucleotides possessing a primary amino group in the terminal nucleotide
US4849513A (en) 1983-12-20 1989-07-18 California Institute Of Technology Deoxyribonucleoside phosphoramidites in which an aliphatic amino group is attached to the sugar ring and their use for the preparation of oligonucleotides containing aliphatic amino groups
US4587329A (en) * 1984-08-17 1986-05-06 The Dow Chemical Company Dense star polymers having two dimensional molecular diameter
US4910300A (en) 1985-12-11 1990-03-20 Chiron Corporation Method for making nucleic acid probes
US5093232A (en) 1985-12-11 1992-03-03 Chiron Corporation Nucleic acid probes
US6312679B1 (en) 1986-08-18 2001-11-06 The Dow Chemical Company Dense star polymer conjugates as dyes
US5338532A (en) * 1986-08-18 1994-08-16 The Dow Chemical Company Starburst conjugates
CA1339303C (en) 1987-09-21 1997-08-19 Lyle John Arnold Jr. Non-nucleotide linking reagents for nucleotide probes
US5124246A (en) 1987-10-15 1992-06-23 Chiron Corporation Nucleic acid multimers and amplified nucleic acid hybridization assays using same
US5278302A (en) * 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US5391723A (en) 1989-05-31 1995-02-21 Neorx Corporation Oligonucleotide conjugates
US5552391A (en) 1990-01-16 1996-09-03 La Jolla Pharmaceutical Company Chemically-defined non-polymeric valency platform molecules and conjugates thereof
US5171264A (en) * 1990-02-28 1992-12-15 Massachusetts Institute Of Technology Immobilized polyethylene oxide star molecules for bioapplications
US5460831A (en) 1990-06-22 1995-10-24 The Regents Of The University Of California Targeted transfection nanoparticles
US6096722A (en) * 1990-08-14 2000-08-01 Isis Pharmaceuticals Inc. Antisense modulation of cell adhesion molecule expression and treatment of cell adhesion molecule-associated diseases
PT748382E (pt) 1993-09-02 2003-03-31 Ribozyme Pharm Inc Acidos nucleicos enzimaticos contendo nao-nucleotidos
US5874409A (en) 1995-06-07 1999-02-23 La Jolla Pharmaceutical Company APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies
EP0954531A1 (en) 1996-06-06 1999-11-10 Lajolla Pharmaceutical Company aPL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR aPL ANTIBODY-MEDIATED PATHOLOGIES
CA2268825C (en) 1996-10-11 2006-04-18 The Regents Of The University Of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
US6489304B2 (en) * 1997-05-01 2002-12-03 Hybridon, Inc. Hyperstructure-forming carriers
ATE432348T1 (de) 1997-06-06 2009-06-15 Univ California Inhibitoren von immunstimulatorischen dna sequenz aktivität
US6080580A (en) * 1998-10-05 2000-06-27 Isis Pharmaceuticals Inc. Antisense oligonucleotide modulation of tumor necrosis factor-α (TNF-α) expression
US6458953B1 (en) 1998-12-09 2002-10-01 La Jolla Pharmaceutical Company Valency platform molecules comprising carbamate linkages
EP1176966B1 (en) 1999-04-12 2013-04-03 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Oligodeoxynucleotide and its use to induce an immune response
CA2376057A1 (en) 1999-06-08 2000-12-14 La Jolla Pharmaceutical Company Valency platform molecules comprising aminooxy groups
WO2001022972A2 (en) 1999-09-25 2001-04-05 University Of Iowa Research Foundation Immunostimulatory nucleic acids
US7585847B2 (en) * 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
AU4215901A (en) 2000-03-17 2001-09-24 Reginald M Gorczynski Methods and compositions for immunoregulation
AU2001280875A1 (en) 2000-07-28 2002-02-13 The Johns Hopkins University Serial analysis of transcript expression using long tags
JP4049357B2 (ja) 2000-08-11 2008-02-20 独立行政法人科学技術振興機構 ポルフィリン環が互いにメゾ−メゾ炭素結合と2つのβ−β炭素の結合との三つの結合により一方向に縮環したポルフィリン化合物およびその合成方法
EP1390390A4 (en) * 2001-03-21 2009-07-08 Human Genome Sciences Inc HUMAN SECRETED PROTEINS
CA2480311C (en) 2002-04-05 2015-01-27 Santaris Pharma A/S Oligomeric compounds for the modulation of hif-1alpha expression
AU2003243409A1 (en) 2002-06-05 2003-12-22 Coley Pharmaceutical Group, Inc. Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory cpg nucleic acids
SE0201701D0 (sv) 2002-06-05 2002-06-05 Gotovax Ab Treatment of epithelial tumors and infections
US20040053880A1 (en) * 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
WO2004014322A2 (en) * 2002-08-12 2004-02-19 Dynavax Technologies Corporation Immunomodulatory compositions, methods of making, and methods of use thereof
CN101955976A (zh) * 2002-11-21 2011-01-26 贝希尔治疗学股份有限公司 预防和治疗疾病的方法及免疫调节核酸组合物
KR101178816B1 (ko) * 2002-12-23 2012-09-07 다이나박스 테크놀로지 코퍼레이션 면역자극성 서열 올리고뉴클레오타이드 및 이의 이용방법
US20070009899A1 (en) * 2003-10-02 2007-01-11 Mounts William M Nucleic acid arrays for detecting gene expression in animal models of inflammatory diseases
US20050239733A1 (en) * 2003-10-31 2005-10-27 Coley Pharmaceutical Gmbh Sequence requirements for inhibitory oligonucleotides
US20060193821A1 (en) * 2004-03-05 2006-08-31 Diener John L Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics
WO2005086835A2 (en) 2004-03-05 2005-09-22 Archemix Corp. Aptamers to the human il-12 cytokine family and their use as autoimmune disease therapeutics
AU2005282889B2 (en) 2004-09-01 2012-03-15 Dynavax Technologies Corporation Methods and conpositions for inhibition of innate immune responses and autoimmunity
CA2591582A1 (en) * 2004-12-17 2006-06-22 Dynavax Technologies Corporation Methods and compositions for induction or promotion of immune tolerance
US7786089B2 (en) 2005-12-20 2010-08-31 Idera Pharmaceuticals, Inc. Immunostimulatory activity of immune modulatory oligonucleotides (IMO™) containing different lengths of palindromic segments
WO2007095387A2 (en) 2006-02-17 2007-08-23 Dharmacon, Inc. Compositions and methods for inhibiting gene silencing by rna interference
KR20120115412A (ko) 2006-04-07 2012-10-17 이데라 파마슈티칼즈, 인코포레이티드 Tlr7 및 tlr8에 대한 안정화된 면역 조절성 rna〔simra〕 화합물
JP5749492B2 (ja) * 2007-10-26 2015-07-15 ダイナバックス テクノロジーズ コーポレイション 免疫応答と自己免疫を阻害する方法及び組成物

Similar Documents

Publication Publication Date Title
JP2012191939A5 (cg-RX-API-DMAC7.html)
BR112015017338A2 (pt) anticorpos anti-il-17a e seu uso no tratamento de transtornos autoimunes e inflamatórios
JP2015532097A5 (cg-RX-API-DMAC7.html)
JP2018507711A5 (cg-RX-API-DMAC7.html)
JP2016513976A5 (cg-RX-API-DMAC7.html)
JP2016513460A5 (cg-RX-API-DMAC7.html)
JP2020522244A5 (cg-RX-API-DMAC7.html)
MX2015009006A (es) Oligonucleotidos inhibitorios y su uso en terapia.
JP2018519944A5 (cg-RX-API-DMAC7.html)
JP2011246355A5 (cg-RX-API-DMAC7.html)
JP2006522806A5 (cg-RX-API-DMAC7.html)
石川千尋 Roles of serotonergic system during the postnatal period in the development of brain and behavior
Pjanic et al. LncRNA de novo discovery reveals noncoding RNAs as major molecular mechanism associating coronary artery disease GWAS variants with causal genes to confer disease risk
TH189259S (th) ไม้แขวนเสื้อ
Goryacheva COMPARATIVE ANALYSIS OF TRAINING LOAD PLANNING OF ELITE ACROBATIC WOMEN''S PAIRS DURING THE PREPARATORY PERIOD
Egorov Buying addicition (compulsive shopping)
Tuleninov Use of trademarks in the internet: contextual advertising
岸本瑠衣 Model mice for 15q11-13 duplication syndrome exhibit late-onset obesity and altered lipid metabolism
Hui MS78. O01
Kaleigh Joseph Conrad and imperialism
李然然 The association of olanzapine-induced metabolic disturbance related measures with TCF7L2 gene expression
刘月 Naiveté and Innocence of Tom Sawyer
Romagnani An update on allergic diseases
Poynter et al. Understanding viral dsRNA production, cell entry and use as an antiviral therapeutic in rainbow trout
Guoping et al. The Feeding and Breeding Management of Addax